skip to content

Other

4D pharma clinical study to resume

10 June 2016 07:31

4D pharma is set to restart its clinical study on Thetanix, its proprietary programme for the treatment of paediatric Crohn's Disease.

The company previously reported a precautionary delay in dosing of patients in the Thetanix phase 1 clinical trial, due to quality concerns that had come to light at one of the company's supply partners during manufacture of an additional batch of Thetanix.

The company says its investigation into the matter has been completed and that the MHRA has given its approval for the clinical study to be restarted.

Story provided by StockMarketWire.com

Related Company: DDDD

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.